



# ASPARTAME, METHYLEUGENOL, AND ISOEUGENOL

VOLUME 134

This publication represents the views and expert opinions of an IARC Working Group on the Identification of Carcinogenic Hazards to Humans, which met in Lyon, France, 6–13 June 2023

LYON, FRANCE - 2024

IARC MONOGRAPHS  
ON THE IDENTIFICATION  
OF CARCINOGENIC HAZARDS  
TO HUMANS

# CONTENTS

---

<b>NOTE TO THE READER</b> .....	<b>1</b>
<b>LIST OF PARTICIPANTS</b> .....	<b>3</b>
<b>PREAMBLE</b> .....	<b>9</b>
<b>A. GENERAL PRINCIPLES AND PROCEDURES</b> .....	<b>9</b>
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review.....	11
4. The Working Group and other meeting participants.....	11
5. Working procedures.....	13
6. Overview of the scientific review and evaluation process.....	14
7. Responsibilities of the Working Group.....	16
<b>B. SCIENTIFIC REVIEW AND EVALUATION</b> .....	<b>17</b>
1. Exposure characterization.....	17
2. Studies of cancer in humans.....	20
3. Studies of cancer in experimental animals.....	25
4. Mechanistic evidence.....	28
5. Summary of data reported.....	31
6. Evaluation and rationale.....	32
References.....	37
<b>PRELIMINARY GENERAL REMARKS</b> .....	<b>41</b>
<b>ASPARTAME</b> .....	<b>43</b>
1. Exposure Characterization.....	43
1.1 Identification of the agent.....	43
1.2 Production and use.....	44
1.3 Detection and quantification.....	48
1.4 Occurrence and exposure.....	51
1.5 Regulations and guidelines.....	92
1.6 Quality of exposure assessment in key epidemiological studies of cancer and mechanistic studies in humans.....	93

2. Cancer in Humans .....	117
Introduction .....	117
2.1 Cancer of the liver, colon and rectum, pancreas, and other organs of the digestive tract .....	118
2.2 Cancers of the urinary tract .....	188
2.3 Cancers of the breast and prostate .....	202
2.4 Cancers of the brain, thyroid, and uterus, and other solid cancers .....	232
2.5 Cancers of lymphatic and haematopoietic tissues .....	261
2.6 Obesity-related cancers and other groupings .....	301
2.7 Cancer of all sites combined .....	311
2.8 Evidence synthesis for cancer in humans .....	330
3. Cancer in Experimental Animals .....	344
3.1 Mouse .....	344
3.2 Rat .....	356
3.3 Hamster .....	375
3.4 Dog .....	377
3.5 Evidence synthesis for cancer in experimental animals .....	377
4. Mechanistic Evidence .....	379
4.1 Absorption, distribution, metabolism, and excretion .....	379
4.2 Evidence relevant to key characteristics of carcinogens .....	390
4.3 Other relevant evidence .....	454
5. Summary of Data Reported .....	477
5.1 Exposure characterization .....	477
5.2 Cancer in humans .....	478
5.3 Cancer in experimental animals .....	479
5.4 Mechanistic evidence .....	480
6. Evaluation and Rationale .....	484
6.1. Cancer in humans .....	484
6.2 Cancer in experimental animals .....	484
6.3. Mechanistic evidence .....	484
6.4 Overall evaluation .....	484
6.5 Rationale .....	484
References .....	485
<b>LIST OF ABBREVIATIONS .....</b>	<b>513</b>
<b>ANNEX 1. Supplementary material for Section 1, Exposure Characterization .....</b>	<b>517</b>
<b>ANNEX 2. Scientific and other publicly available data on aspartame use in artificially sweetened .....</b>	<b>519</b>
<b>            beverages .....</b>	<b>519</b>
<b>ANNEX 3. Supplementary material for Section 2, Cancer in Humans .....</b>	<b>529</b>
<b>ANNEX 4. Supplementary material for Section 4, High-throughput in vitro toxicity screening data ...</b>	<b>533</b>
<b>            evaluation .....</b>	<b>533</b>